Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

DR. JAVITT WORDS OF WISDOM

“Drug companies at the time weren’t interested in a peptide that is produced naturally, so you can’t patent it,” Javitt said. “And while now it seems crucial, from the commercial viewpoint at the time, a drug that people only need for a few days isn’t lucrative to develop.”
Javitt knows a lot about public health policy because one of his professors chided him when he heard that the young medical student was going to India to help cure patients with glaucoma.
“All you’ll be doing is helping a blind beggar see,” the thoughtless man told Javitt.
Enraged, Javitt conducted a study that proved that restoring eyesight to Indian patients with the eye disease increased their family earnings by 1,500%. The patient, now able to see, was able to work – and the pressure on his family to care for him was lifted, helping the entire family advance in life.
The study triggered his life-long passion for public health policy. In the early 2000s, he helped shape the policy of the World Bank Group, which invested billions of dollars into medical infrastructure to treat blinding eye diseases.

https://m.jpost.com/health-science/neurorx-on-the-cusp-of-releasing-a-life-saving-covid-19-treatment-644470/amp

How crippling is COPD???

Abnormalities of surfactant in the immature lung or in the acutely inflamed mature lung are well described. However, in a variety of subacute diseases of the mature lung, abnormalities of lung surfactant may also be of importance. These diseases include chronic obstructive pulmonary disease, asthma, cystic fibrosis, interstitial lung disease, pneumonia, and alveolar proteinosis. Understanding of the mechanisms that disturb the lung surfactant system may lead to novel rational therapies for these diseases.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC107848/

The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022.

https://www.alliedmarketresearch.com/asthma-COPD-drug-market